StreetInsider.com News Articles

Endo presents foot condition treatment data at medical meeting

Thu, 24 Jul 2025 07:30:44 -0400

Endo Inc. (OTCQX: NDOI) presented three studies on potential treatments for plantar fibromatosis and plantar fasciitis at the American Podiatric Medical Association Annual Meeting, which took place July 24-27, 2025.

The presentations covered findings from Phase 1 and Phase 2 studies of collagenase clostridium histolyticum (CCH) in patients with plantar fasciitis and plantar fibromatosis, along with a retrospective analysis of patient experiences with plantar fibromatosis.

"We're pleased to share clinical trial data with healthcare providers as part of our ongoing efforts to help improve patient care and highlight our clinical development strategy," said James P. Tursi, executive vice president of Global Research

Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting

Thu, 24 Jul 2025 07:30:00 -0400

MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during the American Podiatric Medical Association Annual Meeting, taking place July 24-27, 2025.

Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting

Thu, 24 Jul 2025 07:30:00 -0400

Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting

Thu, 24 Jul 2025 07:30:00 -0400

Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting

Thu, 24 Jul 2025 07:30:00 -0400

Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting

Thu, 24 Jul 2025 07:30:00 -0400

Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Podiatric Medical Association Annual Meeting

Thu, 24 Jul 2025 07:30:00 -0400

Endo to Report Second Quarter 2025 Financial Results on August 6, 2025

Mon, 21 Jul 2025 08:24:00 -0400

MALVERN, Pa., July 21, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company") announced today that it will report second quarter 2025 financial results on August 6, 2025, prior to market open. The Company will host a conference call on the same day at 8:00 a.m. ET.

Endo to Report Second Quarter 2025 Financial Results on August 6, 2025

Mon, 21 Jul 2025 08:24:00 -0400

Mallinckrodt gets Irish court approval to merge with Endo

Thu, 17 Jul 2025 07:44:02 -0400

Mallinckrodt plc received approval from the Irish High Court to proceed with its merger with Endo, Inc. (OTCQX: NDOI), clearing the final legal hurdle for the pharmaceutical companies' combination.

The court ruling follows shareholder approval from both companies last month for the stock and cash transaction. Mallinckrodt and Endo expect to complete the merger in early August, pending satisfaction of remaining closing conditions.

The combined company will maintain its global headquarters in Dublin, Ireland, where Mallinckrodt is currently based. Siggi Olafsson, Mallinckrodt's current president and CEO, will serve in the same role for the merged entity.

The companies announced their merger plans in

Mallinckrodt gets Irish court approval to merge with Endo

Thu, 17 Jul 2025 07:44:02 -0400

Mallinckrodt plc received approval from the Irish High Court to proceed with its merger with Endo, Inc. (OTCQX: NDOI), clearing the final legal hurdle for the pharmaceutical companies' combination.

The companies announced their merger plans in

Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc.